Since p53 is nuclear localized and its overexpression is responsible for various cellular metabolic disorders, the promoter with weaker transcriptional strength is suitable for activating p53 expression.[20] As for DAPK3, it can localize to either the nucleus to synergize with the pro‐apoptotic effects of p53, or to the cytoplasm. The gene discussed is DAPK3; the disease is metabolic disease.